Jacqueline Suen Garcia, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 35 | 2024 | 3539 | 4.590 |
Why?
|
Myelodysplastic Syndromes | 11 | 2024 | 1357 | 2.280 |
Why?
|
Sulfonamides | 14 | 2024 | 1949 | 1.830 |
Why?
|
Azacitidine | 11 | 2024 | 333 | 1.670 |
Why?
|
fms-Like Tyrosine Kinase 3 | 4 | 2023 | 492 | 0.990 |
Why?
|
Antineoplastic Agents | 10 | 2024 | 13531 | 0.850 |
Why?
|
Graft vs Host Disease | 2 | 2024 | 2931 | 0.770 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2024 | 5465 | 0.770 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 11539 | 0.690 |
Why?
|
Mycoses | 1 | 2022 | 383 | 0.640 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 1509 | 0.610 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2021 | 636 | 0.580 |
Why?
|
Staurosporine | 1 | 2017 | 243 | 0.550 |
Why?
|
Boron Compounds | 1 | 2015 | 170 | 0.480 |
Why?
|
Protein Kinase Inhibitors | 3 | 2023 | 5609 | 0.440 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2016 | 646 | 0.430 |
Why?
|
Mitochondria | 3 | 2020 | 3523 | 0.420 |
Why?
|
Apoptosis | 5 | 2024 | 9425 | 0.420 |
Why?
|
Glycine | 1 | 2015 | 656 | 0.410 |
Why?
|
Cytarabine | 3 | 2020 | 699 | 0.350 |
Why?
|
Drug Discovery | 1 | 2017 | 1055 | 0.330 |
Why?
|
Patient Selection | 1 | 2020 | 4192 | 0.320 |
Why?
|
Mutation | 9 | 2024 | 29620 | 0.280 |
Why?
|
Philadelphia Chromosome | 2 | 2024 | 114 | 0.280 |
Why?
|
Remission Induction | 5 | 2024 | 2361 | 0.280 |
Why?
|
Leukemia | 3 | 2022 | 1500 | 0.280 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2024 | 1405 | 0.280 |
Why?
|
Transplantation, Homologous | 3 | 2024 | 4617 | 0.270 |
Why?
|
Myeloproliferative Disorders | 2 | 2021 | 616 | 0.250 |
Why?
|
Nuclear Proteins | 2 | 2016 | 5746 | 0.240 |
Why?
|
Graft vs Leukemia Effect | 1 | 2024 | 119 | 0.230 |
Why?
|
Humans | 49 | 2024 | 746070 | 0.220 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2024 | 5164 | 0.220 |
Why?
|
Drug Resistance, Multiple | 1 | 2024 | 253 | 0.220 |
Why?
|
Azetidines | 1 | 2024 | 135 | 0.210 |
Why?
|
Recurrence | 4 | 2024 | 8373 | 0.200 |
Why?
|
Neutropenia | 2 | 2024 | 880 | 0.200 |
Why?
|
Dancing | 1 | 2022 | 101 | 0.190 |
Why?
|
Busulfan | 1 | 2021 | 250 | 0.190 |
Why?
|
Thrombocythemia, Essential | 1 | 2021 | 104 | 0.180 |
Why?
|
Vidarabine | 1 | 2021 | 333 | 0.180 |
Why?
|
Polycythemia Vera | 1 | 2021 | 163 | 0.180 |
Why?
|
Transplantation Conditioning | 2 | 2024 | 1568 | 0.180 |
Why?
|
Hematology | 1 | 2023 | 229 | 0.170 |
Why?
|
Mitoxantrone | 1 | 2019 | 151 | 0.170 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 381 | 0.170 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 7935 | 0.160 |
Why?
|
Etoposide | 1 | 2019 | 630 | 0.160 |
Why?
|
Pyrimidines | 2 | 2020 | 2954 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 326 | 0.150 |
Why?
|
Antifungal Agents | 1 | 2022 | 706 | 0.150 |
Why?
|
Immunotherapy | 2 | 2023 | 4594 | 0.140 |
Why?
|
Thiophenes | 1 | 2020 | 586 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 183 | 0.130 |
Why?
|
Piperidines | 1 | 2024 | 1634 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 3721 | 0.130 |
Why?
|
Bone Marrow | 2 | 2023 | 2901 | 0.120 |
Why?
|
Immunophenotyping | 2 | 2019 | 1854 | 0.120 |
Why?
|
Superoxides | 1 | 2015 | 386 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2019 | 1349 | 0.120 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6781 | 0.120 |
Why?
|
Immunotherapy, Adoptive | 1 | 2023 | 1392 | 0.120 |
Why?
|
Molecular Targeted Therapy | 2 | 2023 | 2777 | 0.110 |
Why?
|
Protein Transport | 2 | 2016 | 1962 | 0.110 |
Why?
|
Glutathione | 1 | 2015 | 562 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3525 | 0.110 |
Why?
|
Drug Interactions | 1 | 2017 | 1413 | 0.110 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1760 | 0.110 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2058 | 0.100 |
Why?
|
Ribosomes | 1 | 2015 | 488 | 0.100 |
Why?
|
Adult | 11 | 2024 | 214969 | 0.100 |
Why?
|
Signal Transduction | 5 | 2023 | 23115 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3610 | 0.100 |
Why?
|
Cytoplasm | 1 | 2015 | 1522 | 0.090 |
Why?
|
Survival Rate | 2 | 2024 | 12632 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 774 | 0.090 |
Why?
|
DNA Methylation | 1 | 2024 | 4259 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3852 | 0.090 |
Why?
|
Oxidation-Reduction | 1 | 2015 | 2183 | 0.090 |
Why?
|
Aged | 11 | 2024 | 164222 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10095 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2451 | 0.080 |
Why?
|
Treatment Outcome | 6 | 2024 | 63664 | 0.080 |
Why?
|
Autophagy | 1 | 2016 | 1320 | 0.080 |
Why?
|
Janus Kinase 2 | 2 | 2021 | 534 | 0.080 |
Why?
|
Reactive Oxygen Species | 1 | 2015 | 2063 | 0.080 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 1885 | 0.070 |
Why?
|
Prognosis | 4 | 2024 | 29072 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2024 | 57552 | 0.070 |
Why?
|
Lymphoma | 1 | 2016 | 1872 | 0.070 |
Why?
|
Middle Aged | 10 | 2024 | 214419 | 0.070 |
Why?
|
Age Factors | 2 | 2020 | 18145 | 0.070 |
Why?
|
Cell Survival | 1 | 2015 | 5759 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2015 | 5837 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9172 | 0.060 |
Why?
|
Granulocyte Precursor Cells | 1 | 2024 | 49 | 0.060 |
Why?
|
Female | 12 | 2024 | 382129 | 0.060 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 36 | 0.060 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 16652 | 0.050 |
Why?
|
Male | 10 | 2024 | 351098 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7579 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 12985 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6000 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2015 | 7570 | 0.050 |
Why?
|
Anthracyclines | 1 | 2023 | 281 | 0.050 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 351 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2019 | 17831 | 0.050 |
Why?
|
Idarubicin | 1 | 2019 | 59 | 0.040 |
Why?
|
Leukopenia | 1 | 2020 | 212 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 578 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2023 | 78293 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 674 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 414 | 0.040 |
Why?
|
Adolescent | 3 | 2024 | 86212 | 0.040 |
Why?
|
RNA Splicing | 1 | 2024 | 906 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 2 | 2022 | 4485 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 53219 | 0.040 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3411 | 0.040 |
Why?
|
Animals | 5 | 2024 | 166308 | 0.040 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2023 | 889 | 0.040 |
Why?
|
Genotype | 2 | 2024 | 12775 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 983 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 224 | 0.030 |
Why?
|
Young Adult | 3 | 2024 | 57114 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2024 | 38752 | 0.030 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2015 | 89 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2403 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 350 | 0.030 |
Why?
|
DNA Repair | 1 | 2024 | 2017 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9313 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 221 | 0.030 |
Why?
|
Neoplasms | 2 | 2021 | 21681 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2021 | 2412 | 0.030 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 298 | 0.030 |
Why?
|
DNA Damage | 1 | 2024 | 2390 | 0.030 |
Why?
|
Retreatment | 1 | 2015 | 600 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 713 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3011 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 370 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2887 | 0.030 |
Why?
|
Phenotype | 2 | 2024 | 16250 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2020 | 1158 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2012 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1809 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2385 | 0.020 |
Why?
|
Transcription Factors | 2 | 2024 | 12040 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2022 | 2964 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3704 | 0.020 |
Why?
|
Chromatin | 1 | 2022 | 2896 | 0.020 |
Why?
|
Thalidomide | 1 | 2015 | 881 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2016 | 10303 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5139 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6453 | 0.020 |
Why?
|
Mice | 3 | 2024 | 80065 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 3655 | 0.020 |
Why?
|
Pneumonia | 1 | 2020 | 2110 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 1571 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2021 | 3345 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2020 | 5031 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2497 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12208 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1811 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10018 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2469 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2800 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 20812 | 0.020 |
Why?
|
Internet | 1 | 2016 | 3038 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3609 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2021 | 11385 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6056 | 0.010 |
Why?
|
Child | 1 | 2021 | 78469 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 72413 | 0.010 |
Why?
|